ArticleEuropean journal of medical research2025
Low expression of MKRN1 promotes leukemia cell proliferation.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe MKRN1 gene encodes a specialized E3 ubiquitin ligase with a zinc finger structure, is the ancestor of the MKRN gene family, and is involved in the occurrence and development of colorectal cancer, lung cancer, ovarian cancer, and other malignancies. However, its role in acute lymphoblastic leukemia (ALL) is still unknown. This study aims to explore the function of MKRN1 in ALL.
methodsThe public databases and R package limma were employed to analyze the expression and prognosis of MKRN1 in ALL. Bone marrow aspiration samples were collected from patients to further investigate the mRNA expression levels of the target gene in children with ALL, Lentivirus transduction was employed to knock down and overexpress MKRN1 in two leukemia cell lines (NALM6 and Jurkat), proliferation was measured using the CCK-8 assay, and clinical data were collected for correlation analysis of MKRN1 and clinical characteristics in ALL.
resultsCompared to normal children, MKRN1 expression was significantly lower in children with ALL, and low expression of MKRN1 was associated with poor prognosis. The overexpression of MKRN1 inhibited the proliferation of the Jurkat cell line, while knockdown of MKRN1 promoted the proliferation of the NALM6 cell line. The expression level of MKRN1 correlated with risk stratification, initial white blood cell count, hemoglobin and platelet counts, the blast/naïve cell ratio, and minimal residual disease (MRD) on day 19. High expression of MKRN1 was identified as a protective factor for MRD negativity on day 19.
conclusionMKRN1 knockout promotes acute lymphoblastic leukemia cell proliferation; conversely, high MKRN1 expression serves as a positive prognostic factor for favorable early treatment response, establishing MKRN1 as a novel biomarker in ALL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.